Keyphrases
Docetaxel
100%
Dendritic Cell Vaccine
100%
Randomized Phase II Trial
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Treatment Cycle
60%
Disease-specific Survival
60%
Immune Response
40%
Progression-free Survival
40%
Tumor Antigen
40%
ELISPOT
40%
Delayed Hypersensitivity
40%
Flow Cytometry
20%
AIMS™
20%
Monocytes
20%
Combination Therapy
20%
Messenger RNA (mRNA)
20%
Cell-based
20%
Antigen-specific
20%
Myeloid-derived Suppressor Cells
20%
Cancer Vaccine
20%
Induced Toxicity
20%
Multiple Tumors
20%
Vaccine Response
20%
Kaplan-Meier Method
20%
Antigen Vaccine
20%
Specific Immune Response
20%
Local Reaction
20%
Common Terminology Criteria for Adverse Events (CTCAE)
20%
Prostate-specific Antigen Response
20%
Immune Parameters
20%
Leukapheresis
20%
Antigen-specific Response
20%
Immunology and Microbiology
Prostate
100%
Immune Response
100%
Vaccination Policy
100%
Dendritic Cell
100%
Disease Specific Survival
100%
Vaccine Efficacy
66%
Progression Free Survival
66%
Tumor Antigen
66%
Delayed Hypersensitivity
66%
Immunocompetent Cell
33%
Monocyte
33%
Nomenclature
33%
Myeloid-Derived Suppressor Cell
33%
Cancer Vaccine
33%
Prostate Specific Antigen
33%
Antigen Response
33%
Cell Composition
33%
Cell Antigen
33%
Leukapheresis
33%
Medicine and Dentistry
Dendritic Cell
100%
Docetaxel
100%
Castration Resistant Prostate Cancer
100%
Immune Response
60%
Disease Specific Survival
60%
Progression Free Survival
40%
Tumor Antigen
40%
Delayed Hypersensitivity
40%
Flow Cytometry
20%
Adverse Event
20%
Combination Therapy
20%
Prostate Specific Antigen
20%
Ex Vivo
20%
Immunocompetent Cell
20%
Kaplan Meier Method
20%
Monocyte
20%
Cancer Vaccine
20%
Proteus Syndrome
20%
Cell Antigen
20%
Myeloid-Derived Suppressor Cell
20%
Antigen Response
20%
Leukapheresis
20%
Cell Composition
20%
Pharmacology, Toxicology and Pharmaceutical Science
Vaccination Policy
100%
Docetaxel
100%
Castration Resistant Prostate Cancer
100%
Disease Specific Survival
60%
Progression Free Survival
40%
Tumor Antigen
40%
Delayed Hypersensitivity
40%
Flow Cytometry
20%
Adverse Event
20%
Combination Therapy
20%
Prostate Specific Antigen
20%
Cancer Vaccine
20%
Multiple Cancer
20%